Ovarian Cystadenocarcinoma

Observed

→ investigated in trials for

Paclitaxelsmall molecule

10 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Bevacizumabmonoclonal antibody

5 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cisplatinsmall molecule

3 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Doxorubicinsmall molecule

3 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Capecitabinesmall molecule

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Docetaxelsmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Filgrastimother

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Metforminsmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Oxaliplatinsmall molecule

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Topotecansmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Veliparibsmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Adavosertibsmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Belinostatsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Bortezomibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Chemotherapy

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cyclophosphamidesmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Dasatinibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Dexamethasonesmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Erlotinibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Everolimussmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Gemcitabinesmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Letrozolesmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Nab-paclitaxel

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Sapanisertibsmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Temsirolimussmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

Ovarian Cystadenocarcinoma studied in …STUDIED_INderived10 of 31show all (up to 200)
→ studied in	NCT02101775Phase 2 · active not recruiting Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 31 trials mapped (3 active)	—	—	Ovarian Clear Cell Cystadenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01081262Phase 3 · active not recruiting Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 31 trials mapped (3 active)	—	—	Ovarian Mucinous Cystadenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02142803Phase 1 · active not recruiting TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors · condition mapped ONTOLOGY_EXACT · 31 trials mapped (3 active)	—	—	Ovarian Clear Cell Cystadenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02122185Phase 2 · completed Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 31 trials mapped (3 active)	—	—	Ovarian Clear Cell Cystadenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02111941early Phase 1 · completed Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer · condition mapped ONTOLOGY_EXACT · 31 trials mapped (3 active)	—	—	Ovarian Clear Cell Cystadenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05074472Phase 1/Phase 2 · completed A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors · condition mapped ONTOLOGY_EXACT · 31 trials mapped (3 active)	—	—	Ovarian Serous Cystadenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02059265Phase 2 · terminated Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 31 trials mapped (3 active)	—	—	Ovarian Clear Cell Cystadenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02283658Phase 2 · completed Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer · condition mapped ONTOLOGY_EXACT · 31 trials mapped (3 active)	—	—	Ovarian Serous Cystadenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01074411Phase 1 · completed Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 31 trials mapped (3 active)	—	—	Ovarian Clear Cell Cystadenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01196429Phase 2 · completed Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 31 trials mapped (3 active)	—	—	Ovarian Clear Cell Cystadenocarcinoma	1	Observed	clinicaltrials	graph →

Ovarian Cystadenocarcinoma studied in …STUDIED_INderived10 of 31show all (up to 200)

→ studied in

NCT02101775Phase 2 · active not recruiting

Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 31 trials mapped (3 active)

—

Observed

Ovarian Mucinous Cystadenocarcinoma

→ studied in

NCT01081262Phase 3 · active not recruiting

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 31 trials mapped (3 active)

—

Observed

→ studied in

NCT02142803Phase 1 · active not recruiting

TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors · condition mapped ONTOLOGY_EXACT · 31 trials mapped (3 active)

—

Observed

→ studied in

NCT02122185Phase 2 · completed

Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 31 trials mapped (3 active)

—

Observed

→ studied in

NCT02111941early Phase 1 · completed

Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer · condition mapped ONTOLOGY_EXACT · 31 trials mapped (3 active)

—

Observed

Ovarian Serous Cystadenocarcinoma

→ studied in

NCT05074472Phase 1/Phase 2 · completed

A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors · condition mapped ONTOLOGY_EXACT · 31 trials mapped (3 active)

—

Observed

→ studied in

NCT02059265Phase 2 · terminated

Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 31 trials mapped (3 active)

—

Observed

Ovarian Serous Cystadenocarcinoma

→ studied in

NCT02283658Phase 2 · completed

Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer · condition mapped ONTOLOGY_EXACT · 31 trials mapped (3 active)

—

Observed

→ studied in

NCT01074411Phase 1 · completed

Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 31 trials mapped (3 active)

—

Observed

→ studied in

NCT01196429Phase 2 · completed

Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 31 trials mapped (3 active)

—

Observed